Literature DB >> 34238917

DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy.

Ruixue Huang1, Ping-Kun Zhou2.   

Abstract

Genomic instability is the hallmark of various cancers with the increasing accumulation of DNA damage. The application of radiotherapy and chemotherapy in cancer treatment is typically based on this property of cancers. However, the adverse effects including normal tissues injury are also accompanied by the radiotherapy and chemotherapy. Targeted cancer therapy has the potential to suppress cancer cells' DNA damage response through tailoring therapy to cancer patients lacking specific DNA damage response functions. Obviously, understanding the broader role of DNA damage repair in cancers has became a basic and attractive strategy for targeted cancer therapy, in particular, raising novel hypothesis or theory in this field on the basis of previous scientists' findings would be important for future promising druggable emerging targets. In this review, we first illustrate the timeline steps for the understanding the roles of DNA damage repair in the promotion of cancer and cancer therapy developed, then we summarize the mechanisms regarding DNA damage repair associated with targeted cancer therapy, highlighting the specific proteins behind targeting DNA damage repair that initiate functioning abnormally duo to extrinsic harm by environmental DNA damage factors, also, the DNA damage baseline drift leads to the harmful intrinsic targeted cancer therapy. In addition, clinical therapeutic drugs for DNA damage and repair including therapeutic effects, as well as the strategy and scheme of relative clinical trials were intensive discussed. Based on this background, we suggest two hypotheses, namely "environmental gear selection" to describe DNA damage repair pathway evolution, and "DNA damage baseline drift", which may play a magnified role in mediating repair during cancer treatment. This two new hypothesis would shed new light on targeted cancer therapy, provide a much better or more comprehensive holistic view and also promote the development of new research direction and new overcoming strategies for patients.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34238917      PMCID: PMC8266832          DOI: 10.1038/s41392-021-00648-7

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  600 in total

1.  RELEASE OF ULTRAVIOLET LIGHT-INDUCED THYMINE DIMERS FROM DNA IN E. COLI K-12.

Authors:  R P BOYCE; P HOWARD-FLANDERS
Journal:  Proc Natl Acad Sci U S A       Date:  1964-02       Impact factor: 11.205

2.  Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814.

Authors:  Qing Sun; Yige Guo; Xiaohong Liu; Frank Czauderna; Michael I Carr; Frank T Zenke; Andree Blaukat; Lyubomir T Vassilev
Journal:  Mol Cancer Res       Date:  2019-09-24       Impact factor: 5.852

3.  A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.

Authors:  Michael J Pishvaian; Hongkun Wang; Aiwu Ruth He; Jimmy J Hwang; Brandon G Smaglo; Sunnie S Kim; Benjamin A Weinberg; Louis M Weiner; John L Marshall; Jonathan R Brody
Journal:  Clin Cancer Res       Date:  2020-07-15       Impact factor: 12.531

Review 4.  The role of single strand break repair pathways in cellular responses to camptothecin induced DNA damage.

Authors:  Chao Mei; Lin Lei; Li-Ming Tan; Xiao-Jing Xu; Bai-Mei He; Chao Luo; Ji-Ye Yin; Xi Li; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Biomed Pharmacother       Date:  2020-02-06       Impact factor: 6.529

5.  DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.

Authors:  Wojciech M Ciszewski; Michele Tavecchio; Jarosław Dastych; Nicola J Curtin
Journal:  Breast Cancer Res Treat       Date:  2013-11-29       Impact factor: 4.872

6.  Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).

Authors:  Naohiro Okano; Chigusa Morizane; Shogo Nomura; Hideaki Takahashi; Hidetaka Tsumura; Hironaga Satake; Nobumasa Mizuno; Kunihiro Tsuji; Kazuhiko Shioji; Akinori Asagi; Kohichiroh Yasui; Sho Kitagawa; Tomomi Kashiwada; Atsushi Ishiguro; Masashi Kanai; Makoto Ueno; Takashi Ogura; Satoshi Shimizu; Kazutoshi Tobimatsu; Masayo Motoya; Koji Nakashima; Masafumi Ikeda; Takuji Okusaka; Junji Furuse
Journal:  Int J Clin Oncol       Date:  2020-06-13       Impact factor: 3.402

7.  The structure of ends determines the pathway choice and Mre11 nuclease dependency of DNA double-strand break repair.

Authors:  Shuren Liao; Margaret Tammaro; Hong Yan
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

Review 8.  Cracking the Ubiquitin Code: The Ubiquitin Toolbox.

Authors:  Monique P C Mulder; Katharina F Witting; Huib Ovaa
Journal:  Curr Issues Mol Biol       Date:  2019-11-01       Impact factor: 2.081

9.  Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.

Authors:  Cornelis M van Tilburg; Till Milde; Ruth Witt; Jonas Ecker; Thomas Hielscher; Angelika Seitz; Jens-Peter Schenk; Juliane L Buhl; Dennis Riehl; Michael C Frühwald; Arnulf Pekrun; Claudia Rossig; Regina Wieland; Christian Flotho; Uwe Kordes; Bernd Gruhn; Thorsten Simon; Christin Linderkamp; Felix Sahm; Lenka Taylor; Angelika Freitag; Jürgen Burhenne; Kathrin I Foerster; Andreas D Meid; Stefan M Pfister; Irini Karapanagiotou-Schenkel; Olaf Witt
Journal:  Clin Epigenetics       Date:  2019-12-10       Impact factor: 6.551

10.  Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.

Authors:  Abigail K Suwala; Damian Stichel; Daniel Schrimpf; Matthias Kloor; Annika K Wefers; Annekathrin Reinhardt; Sybren L N Maas; Christian P Kratz; Leonille Schweizer; Martin Hasselblatt; Matija Snuderl; Malak Sameer J Abedalthagafi; Zied Abdullaev; Camelia M Monoranu; Markus Bergmann; Arnulf Pekrun; Christian Freyschlag; Eleonora Aronica; Christof M Kramm; Felix Hinz; Philipp Sievers; Andrey Korshunov; Marcel Kool; Stefan M Pfister; Dominik Sturm; David T W Jones; Wolfgang Wick; Andreas Unterberg; Christian Hartmann; Andrew Dodgshun; Uri Tabori; Pieter Wesseling; Felix Sahm; Andreas von Deimling; David E Reuss
Journal:  Acta Neuropathol       Date:  2020-11-20       Impact factor: 17.088

View more
  32 in total

Review 1.  CK2 and the Hallmarks of Cancer.

Authors:  May-Britt Firnau; Angela Brieger
Journal:  Biomedicines       Date:  2022-08-16

2.  Detection of Alternative End-Joining in HNSC Cell Lines Using DNA Double-Strand Break Reporter Assays.

Authors:  Nan Zuo; Lin Ma; Weitao Hu; Yongqiang Deng; Lanlan Wei; Qi Liu
Journal:  Bio Protoc       Date:  2022-09-05

3.  Editorial: Epigenetic and Related Signaling Pathways in Response to Ionizing Radiation and Nano-Particles.

Authors:  Ruixue Huang; Qunwei Zhang; Pingkun Zhou
Journal:  Front Cell Dev Biol       Date:  2022-05-27

4.  Diagnostic, Prognostic, and Immunological Roles of HELLS in Pan-Cancer: A Bioinformatics Analysis.

Authors:  Xiao Liang; Linji Li; Yuchao Fan
Journal:  Front Immunol       Date:  2022-06-14       Impact factor: 8.786

Review 5.  Stressing the Regulatory Role of Long Non-Coding RNA in the Cellular Stress Response during Cancer Progression and Therapy.

Authors:  Yi-Zhen Wu; Yong-Han Su; Ching-Ying Kuo
Journal:  Biomedicines       Date:  2022-05-23

6.  A Boolean Model of the Proliferative Role of the lncRNA XIST in Non-Small Cell Lung Cancer Cells.

Authors:  Shantanu Gupta; Daner A Silveira; Ronaldo F Hashimoto; Jose Carlos M Mombach
Journal:  Biology (Basel)       Date:  2022-03-22

7.  The third international hackathon for applying insights into large-scale genomic composition to use cases in a wide range of organisms.

Authors:  Kimberly Walker; Divya Kalra; Rebecca Lowdon; Guangyi Chen; David Molik; Daniela C Soto; Fawaz Dabbaghie; Ahmad Al Khleifat; Medhat Mahmoud; Luis F Paulin; Muhammad Sohail Raza; Susanne P Pfeifer; Daniel Paiva Agustinho; Elbay Aliyev; Pavel Avdeyev; Enrico R Barrozo; Sairam Behera; Kimberley Billingsley; Li Chuin Chong; Deepak Choubey; Wouter De Coster; Yilei Fu; Alejandro R Gener; Timothy Hefferon; David Morgan Henke; Wolfram Höps; Anastasia Illarionova; Michael D Jochum; Maria Jose; Rupesh K Kesharwani; Sree Rohit Raj Kolora; Jędrzej Kubica; Priya Lakra; Damaris Lattimer; Chia-Sin Liew; Bai-Wei Lo; Chunhsuan Lo; Anneri Lötter; Sina Majidian; Suresh Kumar Mendem; Rajarshi Mondal; Hiroko Ohmiya; Nasrin Parvin; Carolina Peralta; Chi-Lam Poon; Ramanandan Prabhakaran; Marie Saitou; Aditi Sammi; Philippe Sanio; Nicolae Sapoval; Najeeb Syed; Todd Treangen; Gaojianyong Wang; Tiancheng Xu; Jianzhi Yang; Shangzhe Zhang; Weiyu Zhou; Fritz J Sedlazeck; Ben Busby
Journal:  F1000Res       Date:  2022-05-16

8.  Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma.

Authors:  Jing Wang; Weizhen Xing; Yanling Lin; Nuray Uskenbayeva; Hongchao Yan; Yang Xu; Lisha Fang
Journal:  J Clin Lab Anal       Date:  2022-04-14       Impact factor: 3.124

Review 9.  DNA Damage Repair in Brain Tumor Immunotherapy.

Authors:  Shihong Zhao; Boya Xu; Wenbin Ma; Hao Chen; Chuanlu Jiang; Jinquan Cai; Xiangqi Meng
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

Review 10.  Take a Break to Repair: A Dip in the World of Double-Strand Break Repair Mechanisms Pointing the Gaze on Archaea.

Authors:  Mariarosaria De Falco; Mariarita De Felice
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.